Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Change in tumor burden signals treatment needs in mRCC

Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Key clinical point: Change in tumor burden during active surveillance for metastatic RCC is prognostic.

Major finding: Each millimeter increase in total tumor burden during surveillance was associated with a 16% higher risk of death overall and a 21% increase in risk of death after stopping surveillance and starting first-line systemic therapy.

Study details: Retrospective cohort study of 52 patients with metastatic RCC who started with active surveillance.

Disclosures: The authors declared having no conflicts of interest.

Read the article here.

Citation:

Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018